Viral Vector Manufacturing, Non-Viral Vector Manufacturing and Gene Therapy Manufacturing Market Report 2022: Increasing Number of Cell & Gene Therapies Priming Sector for Substantial Growth
Dublin, Oct. 06, 2022 (GLOBE NEWSWIRE) -- The "Viral Vector Manufacturing, Non-Viral Vector Manufacturing and Gene Therapy Manufacturing Market by Scale of Operation, Type of Vector, Application Area, Therapeutic Area, and Geographical Regions: Industry Trends and Global Forecasts, 2022-2035" report has been added to ResearchAndMarkets.com's offering.
With the increasing number of cell and gene therapies being developed and launched for a wide range of therapeutic areas, these modalities are on their way to become one of the highest valued markets in the biopharmaceutical domain. In fact, in 2021, cell and gene therapy developers raised capital worth more than USD 20 billion, registering an increase of 19% from the amount raised in 2020 (~USD 17 billion).
It is worth highlighting that, in February 2022, the USFDA approved second CAR-T therapy, CARVYKTIT, developed by Johnson and Johnson, which can be used for the treatment of relapsed or refractory multiple myeloma. Additionally, close to 1,500 clinical trials are being conducted, globally, for the evaluation of cell and gene therapies. Over time, it has been observed that the clinical success of these therapies relies on the design and type of gene delivery vector used (in therapy development and / or administration). At present, several innovator companies are actively engaged in the development / production of viral vectors and / or non-viral vectors for cell and gene therapies.
In this context, it is worth mentioning that, over the past few years, multiple viral vector and non-viral vector based vaccine candidates have been developed against COVID-19 (caused by novel coronavirus, SARS-CoV-2) and oncological disorders; this is indicative of lucrative opportunities for companies that have the required capabilities for viral vector manufacturing and gene therapy manufacturing.
The viral vector manufacturing and non-viral vector manufacturing landscape features a mix of industry players (well-established companies, mid-sized firms and start-ups / small companies), as well as several academic institutes. It is worth highlighting that several companies that have the required capabilities and facilities to manufacture vectors for both in-house requirements and offer contract services (primarily to ensure the optimum use of their resources and open up additional revenue generation opportunities) have emerged in this domain.
Further, in order to produce more effective and affordable vectors, several stakeholders are integrating various novel technologies; these technologies are likely to improve the scalability and quality of the resultant therapy. In addition, this industry has also witnessed a significant increase in the partnership and expansion activities over the past few years, with several companies having been acquired by the larger firms. Given the growing demand for interventions that require genetic modification, the vector and gene therapy manufacturing market is poised to witness substantial growth in the foreseen future.
Scope of the Report
The "Viral Vector Manufacturing, Non-Viral Vector Manufacturing and Gene Therapy Manufacturing Market (5th Edition) by Scale of Operation (Preclinical, Clinical and Commercial), Type of Vector (AAV Vector, Adenoviral Vector, Lentiviral Vector, Retroviral Vector, Plasmid DNA and Others), Application Area (Gene Therapy, Cell Therapy and Vaccine), Therapeutic Area (Oncological Disorders, Rare Disorders, Neurological Disorders, Sensory Disorders, Metabolic Disorders, Musco-skeletal Disorders, Blood Disorders, Immunological Diseases, and Others), and Geographical Regions (North America, Europe, Asia Pacific, MENA, Latin America and Rest of the World): Industry Trends and Global Forecasts, 2022-2035" report features an extensive study of the rapidly growing market of vector and gene therapy manufacturing, focusing on contract manufacturers, as well as companies having in-house manufacturing facilities.
Key Topics Covered:
1. PREFACE
2. EXECUTIVE SUMMARY
3. INTRODUCTION
4. VIRAL VECTOR AND GENE THERAPY MANUFACTURERS (INDUSTRY PLAYERS): MARKET LANDSCAPE
5. PLASMID DNA AND GENE THERAPY MANUFACTURERS (INDUSTRY PLAYERS): MARKET LANDSCAPE
6. VECTOR AND GENE THERAPY MANUFACTURERS (NON-INDUSTRY PLAYERS): MARKET LANDSCAPE
7. VECTOR AND GENE THERAPY MANUFACTURING TECHNOLOGIES: MARKET LANDSCAPE
8. COMPANY COMPETITIVENESS ANALYSIS
9. VECTOR AND GENE THERAPY MANUFACTURERS IN NORTH AMERICA
10. VECTOR AND GENE THERAPY MANUFACTURERS IN EUROPE
11. VECTOR AND GENE THERAPY MANUFACTURERS IN ASIA-PACIFIC
12. OTHER KEY PLAYERS
13. RECENT PARTNERSHIPS
14. RECENT EXPANSIONS
15. STRATEGIC PARTNER ANALYSIS
16. EMERGING VECTORS
17. KEY INSIGHTS
18. COST PRICE ANALYSIS
19. CAPACITY ANALYSIS
20. DEMAND ANALYSIS
21. MARKET SIZING AND OPPORTUNITY ANALYSIS
22. PORTER'S FIVE FORCES ANALYSIS
23. KEY DRIVERS AND CHALLENGES
24. SURVEY ANALYSIS
25. CONCLUDING REMARKS
26. EXECUTIVE INSIGHTS
Companies Mentioned
4D Molecular Therapeutics
AavantiBio
Abbott
AbbVie
Abeona Therapeutics
Abintus Bio
apceth Biopharma
Applied Biological Materials
Applied Genetic Technologies (AGTC)
Applied Viromics
Arcellx
ArcticZymes Technologies
Areta International
Aruvant Sciences
ASC Therapeutics
AskBio
Asklepios BioPharmaceutical
Astellas Pharma
AstraZeneca
Atara Biotherapeutics
Atlantic Bio GMP (subsidiary of Atlanpole Biotherapies)
Atsena Therapeutics
Audentes Therapeutics (acquired by Astella Pharma)
Aurora Biopharma
Autolus Therapeutics
Avantor
Avecia Biologics
Avid Bioservices
AVROBIO
Axovant Gene Therapies
Bamboo Therapeutics
Batavia Biosciences
Baylor College of Medicine
BCM Families Foundation
Biological E.
Beam Therapeutics
Beckman Research Institute
Beijing Biohealthcare Biotechnology
Beijing Doing Biomedical
Beijing HuiNengAn Biotech
Beijing Immunochina Medical Science & Technology
Beijing Mario Biotech
Beijing Sanwater Biological Technology
Bellicum Pharmaceuticals
Benitec Biopharma
BIA Separations (Acquired by Sartorius)
Bioceltech Therapeutics
97. BioCentriq (Acquired by GC)
Biogen
Bio-Gene Technology
BioInvent International
BioMarin Pharmaceuticals
Biomay
Biomiga
Bionic Sight
BioNTech Innovative Manufacturing Service (formerly known as Eufects)
Bio-Rad Laboratories
BioReliance
BioVec Pharma
Bioverativ
Biovian
BioVision
Blue Sky BioServices (subsidiary of LakePharma)
bluebird bio (formerly known as Genetix Pharmaceuticals)
BMS
Boehringer Ingelheim BioXcellence
BoYuan RunSheng Pharma
Brain Neurotherapy Bio
Brammer Bio (acquired by Thermo Fisher Scientific)
Brazilian Biosciences National Laboratory (LNBio)
Bristol Myers Squibb
Cabaletta Bio
Caltech
Cambridge Gene Therapy
Candel Therapeutics
Capsugel
Carina Biotech
Carmine Therapeutics
CARsgen Therapeutics
Cartesian Therapeutics
Casey Eye Institute
Castle Creek Biosciences
Catalent Biologics
Celgene
Cell and Gene Therapy Catapult
Cell Biolabs
Cellectis
CellGenTech
Cellular Biomedicine Group
Cellvec
Celonic
Celsion
Celyad Oncology
Center for Breakthrough Medicines
Centre for Commercialization of Regenerative Medicine
Centre for Process Innovation
CEVEC Pharmaceuticals
CG Oncology
Children's Medical Research Institute (CMRI)
Children's Hospital of Philadelphia
China Immunotech Biotechnology
Choroideremia Research Foundation
Cincinnati Children's Hospital Medical Center
City of Hope
Clean Cells
Clino
Cobra Biologics (acquired by Charles River Laboratories)
Cognate BioServices (acquired by Charles River Laboratories)
CombiGene
Copernicus Therapeutics
Cornell University
Creative Biogene
Creative Biolabs
CSL Behring
Cytiva (formerly known as GE Healthcare Life Sciences)
CytoMed Therapeutics
Cytovance Biologics
Daiichi Sankyo
Decibel
Delphi Genetics
Denali Therapeutics
DINAQOR
DNAtrix
Duke University
Durham
Dyno Therapeutics
Editas Medicine
ElevateBio
Elixirgen Scientific
Emendo Biotherapeutics
Emergent Biosolutions
Emory University School of Medicine
enGene
Epeius Biotechnologies
Errant Gene Therapeutics
ERYTECH Pharma
ESCO Aster
Esteve
eTheRNA immunotherapies
EUFETS
Eureka Biotechnology
Eurofins Genomics
Eurofins Scientific
ExcellGene
Exothera
Expression Therapeutics
Eyevensys
Fate Therapeutics
FerGene
FIMA
FinVector (formerly Ark Therapeutics)
Five Prime Therapeutics
Flash Therapeutics
Flexion Therapeutics
Florida Biologix
Formula Pharmaceuticals
Fortress Biotech
Fosun Pharma
Foundation Fighting Blindness
Fraunhofer Institute for Toxicology and Experimental Medicine
Freeline Therapeutics
Fujifilm Diosynth Biotechnologies
Fundamenta Therapeutics
G-CON Manufacturing
GE Healthcare Life Sciences
GEG Tech
Genable Technologies
Genecopoeia
GeneCure Biotechnologies
GeneDetect
GeneImmune Biotechnology
Genelux
GeneMedicine
Genenta Science
GeneOne Life Science
Genethon
Hemera Biosciences
Henan Hualong Biotechnology
Herantis Pharma
Hitachi Chemical Advanced Therapeutics Solutions
Others
For more information about this report visit https://www.researchandmarkets.com/r/h2zdyx
CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood,Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900